Innoviva, Inc. INVA
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -7.90%
- 1 year
- -13.00%
5D -0.51 (-2.70%)
- Market cap
- 1.31B
- Revenue (ttm)
- 438.32M
- Profit margin
- 44.13%
- EPS (ttm)
- 2.35
- Shares out
- 71.08M
- P/E ratio
- 7.83
- Forward P/E
- 8.33
- YTD return
- -7.90%
- 1-year return
- -13.00%
- 50-day average
- 20.48
- Volume
- 1.15M
- Avg volume
- 855.55K
- Open
- 18.41
- Previous close
- 18.41
- Day's range
- 18.33 – 18.79
- 52-week range
- 18.19 – 25.15
- Beta
- 0.37
- Analysts
- Buy
- Price target
- 33.83 (+83.8%)
- Earnings date
- Feb 24, 2027
Key statistics
- 200-day average
- 21.84
- Enterprise value
- 1.05B
- PEG ratio
- 2.80
- Price / sales
- 2.99
- Price / book
- 1.16
- Revenue growth
- -1.60%
- Free cash flow
- 121.16M
- Total cash
- 590.06M
- Total debt
- 331.04M
- Return on equity
- 18.02%
- Short % of float
- 14.28%
Fundamental scorecard
16 of 25 checks passed on INVA’s reported financials
16of 25 checks passed
- Value 4 of 5
- Growth 3 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 33.83
- Target (high)
- 46.00
- Strong buy1
- Buy4
- Hold0
- Sell1
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.47 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.515 | -1.03 | -1.54 | -300.00% |
| Aug 5, 2026 | Jun 30, 2026 | 0.436 | 1.14 | +0.70 | +161.47% |
| May 6, 2026 | Mar 31, 2026 | 0.43 | 0.44 | +0.01 | +2.33% |
| Feb 25, 2026 | Dec 31, 2025 | 0.34 | 1.94 | +1.60 | +470.59% |
| Nov 5, 2025 | Sep 30, 2025 | 0.46 | 1.08 | +0.62 | +134.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2026 | Piper Sandler | init | — | Overweight |
| Nov 5, 2026 | Oppenheimer | main | Outperform | Outperform |
| Aug 7, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jun 22, 2026 | BTIG | main | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 26, 2026 | BTIG | reit | Buy | Buy |
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- inva.com
News
Your note
Sign in to keep a note on INVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASSO STEPHEN | Chief Financial Officer | Stock Award(Grant) | May 14, 2026 | 88,571 |
| DENNER ALEXANDER J | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 5, 2025 | 0 |
| DIPAOLO MARK A | Director | Stock Award(Grant) | May 3, 2026 | 140,492 |
| HAIMOVITZ JULES | Director | Stock Award(Grant) | May 3, 2026 | 152,692 |
| LINDEN JOSEPHINE | Director | Stock Award(Grant) | May 17, 2026 | 15,194 |
| RAIFELD PAVEL | Chief Executive Officer | Stock Award(Grant) | May 14, 2026 | 285,929 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.67% | 12,562,415 | 231.27M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 6.35% | 4,513,052 | 83.09M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.88% | 4,177,982 | 76.92M | Sep 29, 2026 |
| Renaissance Technologies, LLC | 5.14% | 3,650,272 | 67.20M | Sep 29, 2026 |
| State Street Corporation | 4.92% | 3,499,694 | 64.43M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.46% | 3,172,650 | 58.41M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 6.05% | 4,299,263 | 79.15M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 2,231,526 | 41.08M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.75% | 1,955,208 | 36.00M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.26% | 1,606,724 | 29.58M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.43% | 1,018,666 | 18.75M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.42% | 1,008,117 | 18.56M | Jul 30, 2026 |
